AU5861396A - Stable aqueous formulations of 1alpha,25-dihydroxycholecalci ferol for parenteral administration - Google Patents
Stable aqueous formulations of 1alpha,25-dihydroxycholecalci ferol for parenteral administrationInfo
- Publication number
- AU5861396A AU5861396A AU58613/96A AU5861396A AU5861396A AU 5861396 A AU5861396 A AU 5861396A AU 58613/96 A AU58613/96 A AU 58613/96A AU 5861396 A AU5861396 A AU 5861396A AU 5861396 A AU5861396 A AU 5861396A
- Authority
- AU
- Australia
- Prior art keywords
- dihydroxycholecalci
- ferol
- 1alpha
- parenteral administration
- stable aqueous
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
- A61K31/593—9,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- General Health & Medical Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Dermatology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US44498295A | 1995-05-19 | 1995-05-19 | |
US444982 | 1995-05-19 | ||
PCT/US1996/007074 WO1996036340A1 (en) | 1995-05-19 | 1996-05-16 | STABLE AQUEOUS FORMULATIONS OF 1α,25-DIHYDROXYCHOLECALCIFEROL FOR PARENTERAL ADMINISTRATION |
Publications (1)
Publication Number | Publication Date |
---|---|
AU5861396A true AU5861396A (en) | 1996-11-29 |
Family
ID=23767175
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU58613/96A Abandoned AU5861396A (en) | 1995-05-19 | 1996-05-16 | Stable aqueous formulations of 1alpha,25-dihydroxycholecalci ferol for parenteral administration |
Country Status (2)
Country | Link |
---|---|
AU (1) | AU5861396A (en) |
WO (1) | WO1996036340A1 (en) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6136799A (en) * | 1998-04-08 | 2000-10-24 | Abbott Laboratories | Cosolvent formulations |
PT1171100E (en) * | 1999-04-13 | 2003-11-28 | Leo Pharma As | PHARMACEUTICAL COMPOSITION SOLUBILIZED FOR PARENTAL ADMINISTRATION |
US6051567A (en) * | 1999-08-02 | 2000-04-18 | Abbott Laboratories | Low oxygen content compositions of 1α, 25-dihydroxycholecalciferol |
US6211169B1 (en) * | 1999-09-29 | 2001-04-03 | Aesgen, Inc. | Stable calcitriol solution for packaging into vials |
US7148211B2 (en) * | 2002-09-18 | 2006-12-12 | Genzyme Corporation | Formulation for lipophilic agents |
WO2006051106A1 (en) | 2004-11-12 | 2006-05-18 | Bioxell Spa | Combined use of vitamin d derivatives and anti-proliferative agents for treating bladder cancer |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4308264A (en) * | 1981-01-28 | 1981-12-29 | Abbott Laboratories | Stabilized, dilute aqueous preparation of 1α,25-dihydroxycholecalciferol for neonatal administration |
JPH05238936A (en) * | 1992-02-27 | 1993-09-17 | Dainippon Pharmaceut Co Ltd | Aqueous liquid agent of calcitriol |
DE4338046A1 (en) * | 1993-11-08 | 1995-05-11 | Dietl Hans | Fat soluble drug-containing liquid pharmaceutical preparation for oral use |
-
1996
- 1996-05-16 WO PCT/US1996/007074 patent/WO1996036340A1/en active Application Filing
- 1996-05-16 AU AU58613/96A patent/AU5861396A/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
WO1996036340A1 (en) | 1996-11-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU4809596A (en) | Nanosuspensions for intravenous administration | |
AU7572196A (en) | Pharmaceutical formulations | |
AU698992B2 (en) | Pharmaceutical, orally applicable composition | |
AU5945396A (en) | 6-dimethylaminomethyl-1-phenyl-cyclohexane compounds as pharmaceutical active ingredients | |
AU7547196A (en) | 1-phenyl-2-dimethylaminomethyl-cyclohexan-1-ol compounds as pharmaceutical active ingredients | |
AU5945296A (en) | Medicament for nasal administration | |
AU5402296A (en) | Pharmaceutical composition for transdermic administration | |
AU4821096A (en) | Benzazepine-, benzoxazepine- and benzothiazepine-N-acetic derivatives, process for their preparation and pharmaceutical compositions containing them | |
AU6818196A (en) | Substituted 2,4-imidazolidinedione compounds as pharmaceutical active ingredients | |
AU5651696A (en) | Substituted 1-phenyl-3-pyrazolecarboxamides active on nurotensin receptors, their preparation and pharmaceutical compositions containing them | |
AU6874296A (en) | Novel 2,3-dioxo-1,2,3,4-tetrahydro-quinoyxalinyl derivatives | |
AU5779196A (en) | Novel 2-amino-3-phenylpropionic acid derivatives | |
AU4329396A (en) | Use of 3,4-diphenylchromans | |
EP0747346A3 (en) | N-acyl-2 aryl cyclopropylmethylamine derivatives as melatonergics | |
AU1166097A (en) | Indoloquinone derivatives as bioreductive agents | |
AU5861396A (en) | Stable aqueous formulations of 1alpha,25-dihydroxycholecalci ferol for parenteral administration | |
AU5058196A (en) | Process for the preparation of 1,1-difluoroethane | |
AU4729396A (en) | Process for the preparation of 1,2-benzisothiazolin-3-ones | |
AU5347996A (en) | Preparation for oral administration | |
AU4946896A (en) | Novel bi-tryptaminic derivatives, preparation process and utilization as drugs | |
AU7291096A (en) | Process for the preparation of anti-malarial drugs | |
AU7000496A (en) | Anti-inflammatory antisense drug | |
AU4547896A (en) | 4-oxo-2-butenoic acid derivatives | |
AU4956193A (en) | Stable, highly concentrated formulations of fluorescein derivatives | |
AU5635496A (en) | Derivatives of 2,3:4,6-di-o-isopropylidene-alpha-l-xylo-2-he xulofluranosonic acid |